Antidiabetic activity of angelan isolated from Angelica gigas Nakai

Cited 17 time in scopus
Metadata Downloads
Antidiabetic activity of angelan isolated from Angelica gigas Nakai
Hwan Mook Kim; Jong Soon Kang; Song Kyu Park; Kiho Lee; J Y Kim; Y J Kim; J T Hong; Y Kim; S B Han
Bibliographic Citation
Archives of Pharmacal Research, vol. 31, no. 11, pp. 1489-1496
Publication Year
Angelan isolated from Angelica gigas Nakai inhibits tumor growth and metastasis by enhancing immune functions of macrophages, dendritic cells, and B cells. Here, we report that angelan can inhibit autoimmunity in non-obese diabetic (NOD) mice. Although 80% of the NOD mice had developed diabetes by 24 weeks of age, none of the angelan-treated NOD mice developed diabetes. The mean glucose levels were 118 mg/dl in angelan-treated mice and 506 mg/dl in control NOD mice. Histological examination of the pancreatic islets revealed that most of the islets isolated from angelan-treated mice were less infiltrated with lymphocytes compared with those of control mice. Spleen cells from diabetic NOD mice could adaptively transfer diabetes into NOD. scid mice, but those from angelan-treated NOD mice did not, suggesting that angelan caused the spleen cells to lose the ability to destroy β cells. However, angelan did not affect cytokine production of spleen cells. These results suggest that angelan has dual immunomodulatory functions, i.e., immunostimulation in tumor-bearing mice and immunosuppression in autoimmune diabetic mice.
AngelanAngelica gigas NakaiAutoimmune diabetesImmunomodulationNon-obese diabetic mice
Pharmaceutical Soc Korea
Appears in Collections:
Ochang Branch Institute > Division of National Bio-Infrastructure > Laboratory Animal Resource & Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.